Doppler tissue perfusion measurement is a sensitive and specific tool for a differentiation between malignant and inflammatory pancreatic tumors.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 18 09 2017
accepted: 11 04 2019
entrez: 30 4 2019
pubmed: 30 4 2019
medline: 9 1 2020
Statut: epublish

Résumé

Differentiation between pancreatic malignant and inflammatory tumors presents an important diagnostic problem. The ability to recognize pancreatic malignant tumors using Doppler evaluation of tissue perfusion has been recently demonstrated. The aim of the study was to assess the diagnostic value of Dynamic Tissue Perfusion Measurement (DTPM) in the differentiation between malignant and inflammatory pancreatic tumors. The study included 60 patients (35M, 25F, age 60.9 ± 2.3 years) with a malignant (Group 1, n = 30) or inflammatory (Group 2, n = 30) pancreatic tumor undergoing endoscopic ultrasound with the evaluation of tissue perfusion by Color Doppler and a simultaneous biopsy of lesions for cytological evaluation. In 20 patients the diagnosis was verified in the postoperative histopathological examination. Flow velocity (FV) and percentiles of the distribution of perfusion intensity (PR) evaluated by DTPM were analyzed with regard to receiver-operator-characteristics. FV as well as PR were significantly higher in Group 2 compared to Group 1. A threshold of 2.0 cm/sec for FV identified patients with malignancies with a sensitivity of 83% and specificity of 86%. In multivariable regression analysis, the best PR parameter for differentiating between malignant and inflammatory tumors was 97.5% percentile, whose value of 0.922 allowed for the recognition of pancreatic malignant tumors with a sensitivity of 62% and specificity of 83% (p < 0.001). In conclusion, Color Doppler ultrasound tissue perfusion parameters are a sensitive and specific tool in the differentiation between malignant and inflammatory pancreatic tumors.

Identifiants

pubmed: 31034484
doi: 10.1371/journal.pone.0215944
pii: PONE-D-17-33971
pmc: PMC6488051
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0215944

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Comput Assist Tomogr. 2016 Sep-Oct;40(5):709-16
pubmed: 27224231
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061
pubmed: 28784865
Gastrointest Endosc. 2005 Nov;62(5):728-36; quiz 751, 753
pubmed: 16246688
Med Sci Monit. 2015 Apr 17;21:1089-96
pubmed: 25881555
Pancreatology. 2011;11 Suppl 2:28-33
pubmed: 21464584
Ultrasound Med Biol. 2016 Apr;42(4):891-8
pubmed: 26806440
Pancreas. 2011 Apr;40(3):352-8
pubmed: 21412117
Pancreas. 2009 Aug;38(6):e169-75
pubmed: 19629001
Biomed Res Int. 2013;2013:137868
pubmed: 23853766
Eur Radiol. 2009 Nov;19(11):2641-6
pubmed: 19471941
J Comput Assist Tomogr. 2012 Mar-Apr;36(2):237-42
pubmed: 22446366
Gastroenterol Hepatol. 2007 Dec;30(10):597-601
pubmed: 18028856
Pancreas. 2011 Aug;40(6):809-14
pubmed: 21747310
Radiol Clin North Am. 2012 May;50(3):447-66
pubmed: 22560691
Anesthesiology. 2010 Apr;112(4):1023-40
pubmed: 20234303
Nephron Physiol. 2004;96(4):p99-104
pubmed: 15122055
Am J Gastroenterol. 2002 Jun;97(6):1386-91
pubmed: 12094855
Ann Oncol. 2010 May;21 Suppl 5:v55-8
pubmed: 20555103
Endosc Ultrasound. 2016 Nov-Dec;5(6):355-362
pubmed: 27824024
J Gastroenterol Hepatol. 2016 Mar;31(3):691-5
pubmed: 26455432
Am J Gastroenterol. 2012 Feb;107(2):303-10
pubmed: 22008892
Eur J Radiol. 2012 Mar;81(3):e381-5
pubmed: 22197731
Gastrointest Endosc. 2008 Jan;67(1):141-50
pubmed: 18155437
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Ann Oncol. 2011 Apr;22(4):947-56
pubmed: 21303801
Ann Oncol. 2012 Oct;23 Suppl 7:vii33-40
pubmed: 22997452
Z Gastroenterol. 2015 Oct;53(10):1175-81
pubmed: 26480053
World J Gastroenterol. 2011 Feb 21;17(7):867-97
pubmed: 21412497
Eur J Cancer. 2009 Apr;45(6):931-91
pubmed: 19171476
Acad Radiol. 2011 Jan;18(1):81-8
pubmed: 20951612

Auteurs

Przemysław Dyrla (P)

Department of Gastroenterology, Military Institute of Medicine, Poland.

Jerzy Gil (J)

Department of Gastroenterology, Military Institute of Medicine, Poland.

Krzysztof Kosik (K)

Department of Gastroenterology, Military Institute of Medicine, Poland.

Daniel Schneditz (D)

Institute of Physiology, Medical University of Graz, Graz, Austria.

Marek Saracyn (M)

Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland.

Stanisław Niemczyk (S)

Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.

Arkadiusz Lubas (A)

Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH